These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 21188448)

  • 1. Efficacy and safety of tacrolimus for induction therapy in patients with active lupus nephritis.
    Takahashi S; Hiromura K; Sakurai N; Matsumoto T; Ikeuchi H; Maeshima A; Kaneko Y; Kuroiwa T; Nojima Y
    Mod Rheumatol; 2011 Jun; 21(3):282-9. PubMed ID: 21188448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of disease activity between tacrolimus and mycophenolate mofetil in lupus nephritis: a randomized controlled trial.
    Kamanamool N; Ingsathit A; Rattanasiri S; Ngamjanyaporn P; Kasitanont N; Chawanasuntorapoj R; Pichaiwong W; Anutrakulchai S; Sangthawan P; Ophascharoensuk V; Avihingsanon Y; Sumethkul V
    Lupus; 2018 Apr; 27(4):647-656. PubMed ID: 29105558
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up.
    Mok CC; Ying KY; Yim CW; Siu YP; Tong KH; To CH; Ng WL
    Ann Rheum Dis; 2016 Jan; 75(1):30-6. PubMed ID: 25550339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term data on tacrolimus treatment in lupus nephritis.
    Yap DY; Ma MK; Mok MM; Kwan LP; Chan GC; Chan TM
    Rheumatology (Oxford); 2014 Dec; 53(12):2232-7. PubMed ID: 24996908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of multi-target therapy using a combination of tacrolimus, mycophenolate mofetil and a steroid in patients with active lupus nephritis.
    Ikeuchi H; Hiromura K; Takahashi S; Mishima K; Sakurai N; Sakairi T; Kaneko Y; Maeshima A; Kuroiwa T; Nojima Y
    Mod Rheumatol; 2014 Jul; 24(4):618-25. PubMed ID: 24252014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
    Lanata CM; Mahmood T; Fine DM; Petri M
    Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis.
    Nomura A; Shimizu H; Kishimoto M; Suyama Y; Rokutanda R; Ohara Y; Yamaguchi K; Okada M
    Lupus; 2012 Nov; 21(13):1444-9. PubMed ID: 22917589
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined low-dose mycophenolate mofetil and tacrolimus for lupus nephritis with suboptimal response to standard therapy: a 12-month prospective study.
    Mok CC; To CH; Yu KL; Ho LY
    Lupus; 2013 Oct; 22(11):1135-41. PubMed ID: 23995863
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term tacrolimus-based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice.
    Tanaka H; Watanabe S; Aizawa-Yashiro T; Oki E; Kumagai N; Tsuruga K; Ito E
    Nephron Clin Pract; 2012; 121(3-4):c165-73. PubMed ID: 23327881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tacrolimus versus cyclophosphamide as treatment for diffuse proliferative or membranous lupus nephritis: a non-randomized prospective cohort study.
    Wang S; Li X; Qu L; Wang R; Chen Y; Li Q; He X; Zhang X; Wang H; Wu J; Xu Y; Chen J
    Lupus; 2012 Aug; 21(9):1025-35. PubMed ID: 22570338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose tacrolimus in treating lupus nephritis refractory to cyclophosphamide: a prospective cohort study.
    Fei Y; Wu Q; Zhang W; Chen H; Hou Y; Xu D; Li M; Zhang X; Zhao Y; Zeng X; Zhang F
    Clin Exp Rheumatol; 2013; 31(1):62-8. PubMed ID: 22935463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management of young patients with lupus nephritis using tacrolimus administered as a single daily dose.
    Tanaka H; Oki E; Tsuruga K; Yashiro T; Hanada I; Ito E
    Clin Nephrol; 2009 Dec; 72(6):430-6. PubMed ID: 19954719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of multitarget therapy with cyclophosphamide and tacrolimus for lupus nephritis: a prospective, single-arm, single-centre, open label pilot study in Japan.
    Sakai R; Kurasawa T; Nishi E; Kondo T; Okada Y; Shibata A; Nishimura K; Chino K; Okuyama A; Takei H; Nagasawa H; Amano K
    Lupus; 2018 Feb; 27(2):273-282. PubMed ID: 28683654
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis.
    Tanaka H; Aizawa T; Watanabe S; Oki E; Tsuruga K; Imaizumi T
    Lupus; 2014 Jul; 23(8):813-8. PubMed ID: 24651669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of lupus nephritis by mycophenolate mofetil.
    Rabrenović V; Poskurica M; Kovacević Z; Nesić V; Savin M; Mitić B; Dimković N; Cucković C; Vujić D; Pljesa S; Perunicić-Peković G; Curić S; Mitić I; Ratković M; Marinković J; Jovanović D
    Kidney Blood Press Res; 2010; 33(4):297-303. PubMed ID: 20664209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Renal outcome in patients with lupus nephritis using a steroid-free regimen of monthly intravenous cyclophosphamide: a prospective observational study.
    Fischer-Betz R; Chehab G; Sander O; Vordenbäumen S; Voiculescu A; Brinks R; Schneider M
    J Rheumatol; 2012 Nov; 39(11):2111-7. PubMed ID: 22984276
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response to combination of mycophenolate mofetil, cyclosporin A and corticosteroid treatment in lupus nephritis patients with persistent proteinuria.
    Kasitanon N; Boripatkosol P; Louthrenoo W
    Int J Rheum Dis; 2018 Jan; 21(1):200-207. PubMed ID: 28901731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of tacrolimus for maintenance therapy of lupus nephritis: a 5-year retrospective study at a single center.
    Karasawa K; Uchida K; Kodama M; Moriyama T; Nitta K
    Rheumatol Int; 2018 Dec; 38(12):2271-2277. PubMed ID: 30203113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The difference between lupus nephritis class IV-G and IV-S in Koreans: focus on the response to cyclophosphamide induction treatment.
    Kim YG; Kim HW; Cho YM; Oh JS; Nah SS; Lee CK; Yoo B
    Rheumatology (Oxford); 2008 Mar; 47(3):311-4. PubMed ID: 18204087
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tacrolimus versus intravenous pulse cyclophosphamide therapy in Chinese adults with steroid-resistant idiopathic minimal change nephropathy: a multicenter, open-label, nonrandomized cohort trial.
    Li H; Shi X; Shen H; Li X; Wang H; Li H; Xu G; Chen J
    Clin Ther; 2012 May; 34(5):1112-20. PubMed ID: 22503105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.